In an exploratory analysis of adult patients with CKD associated with T2DThe relative reduction in UACR was 31% greater with KERENDIA vs placebo at month 4 and remained stable thereafter1,2
Geometric mean UACR (mg/g) at baseline ± geometric SD:
• KERENDIA: 798.79±2.65
• Placebo: 814.73±2.67
According to the ADA, all patients with T2D should have an assessment of urinary albumin/UACR and eGFR at least annually. Patients with an eGFR 30 to 60 mL/min/1.73 m2 and/or UACR ≥300 mg/g should be monitored twice annually.3
In patients treated with KERENDIA, the mean SBP decreased by 3 mmHg, and the mean DBP decreased by 1 to 2 mmHg at month 1, remaining stable thereafter.
Mean SBP at baseline ± SD:
Approximately 97% of patients were on an antidiabetic agent.
Mean HbA1c at baseline ± SD:
KERENDIA is indicated to reduce the
risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium
Please read the Prescribing Information for KERENDIA.
References: 1. KERENDIA (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; July 2021. 2. Bakris GL, et al; FIDELIO-DKD Investigators. N Engl J Med. 2020;383(23):2219-2229. 3. American Diabetes Association Professional Practice Committee. Chronic kidney disease and risk management: standards of medical care in diabetes—2022. Diabetes Care. 2022;45(suppl 1):S175-S184. doi:10.2337/dc22-S011.